Melanoma

P1, N=66, Recruiting, Chiome Bioscience Inc. | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

P=N/A, N=75, Recruiting, University of Arkansas | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027

P=N/A, N=66, Not yet recruiting, University of Virginia

P3, N=25, Terminated, Centre Hospitalier Universitaire de Nice | N=44 --> 25 | Unknown status --> Terminated; Rupture du traitement

NLR ≥3 and the presence of liver metastases were identified as independent prognostic factors. These preliminary findings may help refine prognostic stratification for advanced melanoma patients receiving immunotherapy.

A higher mean number of cCAFs was detected and showed a trend toward shorter progression-free survival. The encouraging results of this pilot study need to be validated on a larger cohort of melanoma patients.

Furthermore, D-SERS was applied to study the Type B agent 5-ALA in combination with heme oxygenase-1 (HO-1) modulators, verifying the associated enzyme-regulatory processes. This study presents a proof-of-concept model for the spectral mechanism-based screening of photosensitizers and enzyme modulators, thus aiding the optimization of PDT efficacy and targeted drug development.

Drug sensitivity profiling revealed ST3GAL4 exhibited strong correlations with AZ628 (pan-RAF inhibitor) and RDEA119 (MEK inhibitor), which was further validated by molecular docking showing excellent binding affinities (binding energies: -8.7 and - 7.2 kcal/mol). This study provides structural evidence for targeted therapeutic strategies in ST3GAL4-overexpressing melanoma and establishes foundations for age-stratified immunotherapy.

In vivo, Sch C markedly reduced tumor volume and weight without obvious toxicity and increased apoptosis while decreasing proliferation in tumor tissues. Sch C exerts antimelanoma effects and is associated with inhibition of PI3K/AKT/mTOR signaling and modulation of Rap1-related pathways, suggesting its potential as a therapeutic candidate for melanoma.

Molecular confirmation of the EWSR1 rearrangement is desirable for diagnosis, as the differentiation from other neoplasms, including melanoma and CRTC1::TRIM11 cutaneous tumours, has important therapeutic and prognostic consequences.

Data corroborate the clinicopathological profile of oral melanoma and expand current knowledge by documenting novel South American cases, underscoring its marked clinical heterogeneity, poor prognosis, and the critical importance of early recognition.

In contrast, the distribution pattern of SET oncoprotein immunolabelling was relatively consistent across tumour types, with no statistically significant differences observed. Melanoma, mammary carcinoma, squamous cell carcinoma, prostatic carcinoma, osteosarcoma and transmissible venereal tumour showed the highest immunolabelling intensity patterns, highlighting the importance of SET oncoprotein as a potential therapeutic target and paving the way for future studies on its use in personalized therapy.